TearLab Corp. Company Profile (NASDAQ:TEAR)

Analyst Ratings

Consensus Ratings for TearLab Corp. (NASDAQ:TEAR) (?)
Ratings Breakdown: 4 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.20)
Consensus Price Target: $3.25 (301.23% upside)

Analysts' Ratings History for TearLab Corp. (NASDAQ:TEAR)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Rodman & RenshawInitiated CoverageBuy$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Feltl & Co.UpgradeBuy -> Strong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Craig HallumLower Price TargetBuy$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for TearLab Corp. (NASDAQ:TEAR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q1($0.23)($0.21)$6.53 million$6.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q4($0.25)($0.26)$6.83 million$6.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.24)($0.24)$6.40 million$6.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.25)($0.24)$5.72 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.21)($0.25)$5.40 million$5.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.17)($0.21)$5.50 million$5.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q214($0.17)($0.17)$5.50 million$5.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q114($0.16)($0.17)$5.12 million$9.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.14)($0.17)$4.76 million$4.21 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.13)($0.13)$4.49 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.14)($0.13)$3.80 million$4.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013($0.12)($0.30)$2.18 million$2.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.11)($0.10)$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TearLab Corp. (NASDAQ:TEAR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.24)($0.22)($0.23)
Q2 20163($0.11)($0.06)($0.09)
Q3 20163($0.10)($0.05)($0.08)
Q4 20163($0.10)($0.04)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TearLab Corp. (NASDAQ:TEAR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for TearLab Corp. (NASDAQ:TEAR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/31/2016Brock WrightDirectorBuy59,686$0.78$46,555.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Brock WrightDirectorBuy130,314$0.76$99,038.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014Elias VamvakasCEOBuy50,000$2.24$112,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Elias VamvakasCEOBuy31,187$2.55$79,526.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Elias VamvakasCEOBuy18,813$2.55$47,973.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2014Elias VamvakasCEOBuy150,000$2.49$373,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Elias VamvakasCEOBuy16,276$2.50$40,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Joseph JensenCOOBuy43,375$2.31$100,196.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Brock WrightDirectorBuy23,000$3.82$87,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Brock WrightDirectorBuy11,354$3.83$43,485.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Elias VamvakasCEOBuy70,000$3.43$240,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Richard LindstromDirectorSell5,000$4.61$23,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Elias VamvakasCEOBuy30,000$3.99$119,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Joseph JensenCOOBuy48,693$4.11$200,128.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Paul KarpeckiDirectorSell5,000$6.83$34,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Paul KarpeckiDirectorSell5,000$9.47$47,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2013Richard LindstromDirectorSell5,000$9.26$46,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Richard LindstromDirectorSell5,000$8.95$44,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/11/2013Paul KarpeckiDirectorSell5,000$10.96$54,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013William DumencuCFOSell7,000$13.22$92,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013William DumencuCFOSell7,000$14.39$100,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Paul KarpeckiDirectorSell5,000$10.62$53,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013William DumencuCFOSell7,000$10.61$74,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013William DumencuCFOSell7,000$11.35$79,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2013Tom Jr. DavidsonDirectorBuy1,500$6.63$9,945.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TearLab Corp. (NASDAQ:TEAR)
DateHeadline
07/26/16 10:12 AMA Game Changer in the Treatment of Dry Eye
07/25/16 06:57 PMCan TearLab Corporation (NASDAQ:TEAR) Surprise Analysts this Quarter? - Investor Newswire
07/22/16 06:33 PMTearLab Corporation (NASDAQ:TEAR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 09:41 AMWhat's Ahead for TearLab Corp After Forming Bearish Multiple Bottom Chart Pattern? - Consumer Eagle
07/22/16 08:51 AM4 Medical Instrument Stocks to Bet on This Earnings Season -
07/21/16 07:06 PMSHIRE PLC : Financial Statements and Exhibits (form 8-K)
07/21/16 09:33 AMInsiders Increasing Positions in: TearLab Corporation (NASDAQ:TEAR) - Press Telegraph
07/21/16 09:33 AMEquity Roundup: Stock Performance Focus on TearLab Corporation (NASDAQ:TEAR) - Press Telegraph
07/21/16 09:33 AMHow Analysts Feel About TearLab Corp (NASDAQ:TEAR)? - Press Telegraph
07/20/16 07:46 PMStock Focus: Following Analyst Expectations on Shares of TearLab Corporation (NASDAQ:TEAR) - TGP
07/20/16 07:46 PMTearLab Corporation to Release Second Quarter 2016 Financial Results - GlobeNewswire (press release)
07/20/16 07:30 AMTearLab Corporation to Release Second Quarter 2016 Financial Results - [GlobeNewswire] - SAN DIEGO, July 20, 2016-- TearLab Corporation will announce its second quarter 2016 financial results after market close on Wednesday, August 3, 2016.. TearLab’ s Chief Executive Officer, Seph Jensen ...
07/19/16 07:44 AMRodman & Renshaw Initiates Coverage on TearLab Corp to Buy - TheFounders Daily
07/18/16 01:24 PMETF’s with exposure to TearLab Corp. : July 18, 2016 -
07/17/16 09:31 AMNext Weeks Broker Price Targets For TearLab Corporation (TEAR) - Fiscal Standard
07/16/16 09:53 AMAnalyst Target and Average Rating Watch: TearLab Corporation (NASDAQ:TEAR) - Press Telegraph
07/15/16 05:42 PMTearLab Corporation (NASDAQ:TEAR) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 05:42 PMWhat Is Mean Rating On TearLab Corporation (NASDAQ:TEAR)? - Stocks Daily
07/15/16 05:42 PMThe FDA Confirms The Approval of Xiidra From TearLab Corp (NASDAQ:TEAR) - Journal Transcript
07/14/16 07:00 PMStock Watch: Unusual Volume Seen on Shares of TearLab Corporation (NASDAQ:TEAR) - Engelwood Daily
07/14/16 07:00 PMTrading Performance and Target Watch for TearLab Corporation (NASDAQ:TEAR) - Press Telegraph
07/13/16 07:07 PMTearLab Corporation (NASDAQ:TEAR) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 07:07 PMEye Catching Stocks - TearLab, (NASDAQ:TEAR), Devon Energy, (NYSE:DVN) - Hot Stocks Point
07/13/16 07:07 PMTearLab Corporation Comments on Shire plc FDA Approval of Xiidra™ (lifitegrast ophthalmic solution) 5% - GlobeNewswire (press release)
07/13/16 07:06 PMSolarCity Corp (NASDAQ:SCTY) & TearLab Corp (NASDAQ:TEAR) Traders Recap - Money News (press release)
07/13/16 09:39 AMTearLab (TEAR) Calls Shire's FDA Approval of Xiidra an Important Milestone for DED
07/12/16 07:00 PMWhy This Analyst Sees TearLab Shares Tripling
07/12/16 03:23 PMTearLab Corporation Comments on Shire plc FDA Approval of Xiidra™ (lifitegrast ophthalmic solution) 5% - [at noodls] - SAN DIEGO, July 12, 2016 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ('TearLab' or the 'Company'), a company that develops and markets point of care ophthalmic in-vitro diagnostics, ...
07/11/16 09:30 AMStock Rating Watch and Earnings Insight for TearLab Corporation (NASDAQ:TEAR) - Press Telegraph
07/11/16 09:30 AMTearLab Corporation (NasdaqCM:TEAR) Fundamental Star Rating Report - CML News
07/09/16 09:44 AMCompany Stock Focus for TearLab Corporation (NASDAQ:TEAR): Which Way Will Shares Head? - Press Telegraph
07/09/16 09:44 AMTearlab Corporation (NASDAQ:TEAR) Short Interest Decreased By 2.94% - Press Telegraph
07/07/16 06:51 PMCan TearLab Corporation (NASDAQ:TEAR) Improve on the Earnings Front? - Engelwood Daily
07/06/16 01:43 PMETF’s with exposure to TearLab Corp. : July 6, 2016 -
07/06/16 09:19 AMTearLab Corporation (NASDAQ:TEAR) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 09:19 AMHow Many TearLab Corp (NASDAQ:TEAR)'s Analysts Are Bearish? - Engelwood Daily
07/03/16 09:01 AMTearlab Corporation (NASDAQ:TEAR) Sellers Covered 2.94% of Their Shorts - Engelwood Daily
07/01/16 06:44 PMCovering the Bases on TearLab Corporation (NASDAQ:TEAR): Where is the Stock Going? - Press Telegraph
07/01/16 09:23 AMTearLab Corporation (NASDAQ:TEAR) Earnings Glance and Target Price Review - Engelwood Daily
06/30/16 09:29 AMTEARLAB CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders (form 8-K)
06/30/16 05:07 AMTEARLAB CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matte -
06/23/16 07:29 PMTearLab : to Present at the 6th Annual LD Micro Invitational
06/17/16 09:24 AMContrast Sensitivity in Patients With Emmetropic Presbyopia Before and After Small-Aperture Inlay Implantation
06/04/16 09:51 AMTestosterone cream may provide relief from MGD-related dry eye
06/02/16 03:15 PMTearLab Corporation to Present at the 6th Annual LD Micro Invitational - [Accesswire] - SAN DIEGO, CA / ACCESSWIRE / June 2, 2016 / TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company"), a company that develops and markets point of care ophthalmic in-vitro ...
05/25/16 12:42 PM5 Key Ophthalmology Takeaways: American Society of Cataract and Refractive Surgery (ASCRS) 2016 - Inflammation is known to be a long-standing culprit in OSD. Now we have point-of-care testing to evaluate both tear osmolarity (TearLab; San Diego, California) and markers of inflammation such as MMP-9 (RPS; Sarasota, Florida). Ocular surface inflammation ...
05/25/16 12:42 PMVIDEO: Surgeon recommends screening patients for ocular surface issues before cataract surgery - NEW ORLEANS — At the American Society of Cataract and Refractive Surgery meeting, Sumitra Khandelwal, MD, discusses how she uses TearLab's osmolarity test in her practice as a screening mechanism for cataract patients in order to optimize IOL lens ...
05/20/16 12:53 PMFeltl & Co. Upgrades TearLab Corp to Strong Buy - Trade Calls - Feltl & Co. Upgrades TearLab Corp to Strong BuyTrade CallsBrokerage firm Feltl & Co. Upgrades its rating on TearLab Corp(NASDAQ:TEAR). The shares have been rated Strong Buy. Previously, the analysts had a Buy rating on the shares. The rating by Feltl & Co. was issued on May 5, 2016. In a different note, On ...TearLab Corporation (TEAR) - Broker UpdateRisers & Fallersall 3 news articles »
05/17/16 12:04 PMTEARLAB CORP Financials -
05/12/16 03:54 PMETF’s with exposure to TearLab Corp. : May 12, 2016 -

Social

About TearLab Corp.

TearLab Corp. logoTearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TEAR
  • CUSIP:
Key Metrics:
  • Previous Close: $0.81
  • 50 Day Moving Average: $0.72
  • 200 Day Moving Average: $0.82
  • P/E Ratio: N/A
  • P/E Growth: -0.08
  • Market Cap: $27.71M
  • Beta: 3.09
  • Current Year EPS Consensus Estimate: $-0.39 EPS
  • Next Year EPS Consensus Estimate: $-0.19 EPS
Additional Links:
TearLab Corp. (NASDAQ:TEAR) Chart for Wednesday, July, 27, 2016